Giant Biogene Holding (2367.HK) Earnings Analysis

Giant Biogene Holding (2367.HK) next reports earnings on 2026-09-01, consensus EPS 1.02 HKD. Last quarter (2026-03-19) it missed with EPS 0.757 HKD vs 0.768 HKD est (-1.4%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E 13.76.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 2367.HK next report earnings?

Next earnings date2026-09-01
Consensus EPS estimate1.02 HKD
Revenue estimate3.34B

2367.HK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-190.757 HKD0.768 HKD-1.4%Miss
2025-08-271.23 HKD1.23 HKD0%Beat
2024-08-191.04 HKD0.903 HKD+15.2%Beat

Beat rate: 2/3 (67%) over reported quarters with consensus data.

2367.HK valuation and analyst view

Trailing P/E13.76
Trailing EPS1.788 HKD
Price / book2.72
Dividend yield4.76%
Market cap31.43B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Giant Biogene Holding (2367.HK)'s next earnings date?

Giant Biogene Holding is next scheduled to report on 2026-09-01, with a consensus EPS estimate of 1.02 HKD and revenue estimate of 3.34B.

Did 2367.HK beat earnings last quarter?

In its 2026-03-19 report, 2367.HK posted EPS of 0.757 HKD versus a 0.768 HKD estimate — a miss of 1.4%.

What is 2367.HK's earnings track record?

Over the last 3 reported quarters with consensus data, 2367.HK beat estimates 2 times (67%).

What is 2367.HK's current P/E ratio and EPS?

2367.HK trades at a trailing P/E of 13.76 on trailing EPS of 1.7881502905152635 HKD.

What do analysts rate 2367.HK?

2367.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.